18 results about "Relaxin" patented technology

The present disclosure provides relaxin-2 fusion protein analogs having an enhanced in vivo half-life and methods of making the same. Also disclosed herein are methods of treating relaxin-2 related conditions or diseases using the relaxin-2 fusion protein analogs described herein.

The present disclosure provides relaxin-2 fusion protein analogs with enhanced in vivo half-life and methods for making the same. Also disclosed herein are methods of treating relaxin-2-associated disorders or diseases using the relaxin-2 fusion protein analogs described herein.

The present invention relates to uses of heterodimeric Relaxin fusion polypeptides, in particular for the treatment of heart failure with pulmonary hypertension.

This invention discloses an interchain disulfide bond Cys A24 -Cys B23 H2Relaxin derivatives with thioether bonds as alternatives and their synthetic methods, wherein the structural formula of the H2Relaxin derivatives is shown below: This invention first utilizes diaminodioic acid molecules to synthesize interchain disulfide bonds (Cys) in a single solid-phase process using an N-fluorenemethyloxycarbonyl (Fmoc) solid-phase polypeptide synthesis method. A24 -Cys B23 The folded refolding precursor of H2Relaxin derivatives with thioether bonds as substitutes was then efficiently obtained via one-step oxidative folding and refolding to yield interchain disulfide bonds (Cys). A24 -Cys B23 The H2Relaxin derivative is replaced by a thioether bond.

The invention relates to a traditional Chinese medicine composition for treating ischemic heart failure and a preparation method thereof, and belongs to the field of traditional Chinese medicine pharmacy, and the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 5-15 parts of cassia twig, 5-15 parts of bighead atractylodes rhizome, 5-15 parts of poria cocos, 6-12 parts of rhizoma zingiberis, 5-15 parts of acanthopanax, 10-30 parts of fructus polygoni orientalis, 3-9 parts of verbena, 6-12 parts of dogwood and 3-9 parts of honey-fried licorice root. The composition can remarkably reduce the level of N-terminal proB-type natriuretic peptide, remarkably improve pathological changes of heart tissues of model rats, regulate and control the heart functions of the model rats, improve the systolic function of the heart, relieve expression of inflammatory factors such as interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha of the rats and improve the anti-inflammatory effect of the rats. The action mechanism of the compound relates to a plurality of pathways such as extracellular matrix receptor interaction, a chemotactic factor signal pathway, a relaxin signal pathway, a cyclic adenosine monophosphate signal pathway, a nuclear factor-kB signal pathway, fatty acid metabolism and a Toll-like receptor signal pathway, and the compound is an effective medicament for treating ischemic heart failure.

The present disclosure relates to a fusion protein of relaxin or an analogue and the medical use thereof. Specifically, the present disclosure relates to a fusion protein comprising relaxin or an analogue thereof and a serum albumin binding domain, and the medical use thereof for treating diseases (for example, heart failure). Moreover, the present disclosure relates to a serum albumin binding molecule, which comprises an immunoglobulin single variable domain (for example, VHH) capable of binding to serum albumin, has good plasma stability, and can be used for prolonging the plasma half-life of a drug.

A tetrahydroisoquinoline compound, a preparation method therefor, a pharmaceutical composition containing said compound, and a use thereof are provided. Specifically, the nitrogen-containing heterocyclic compound of formula (I), a pharmaceutically acceptable salt, an enantiomer, a diastereoisomer, or a racemate thereof are provided. The compound may be used for preparing a pharmaceutical composition for treating a disease or condition related to the activity or expression levels of relaxin family receptor 4.

The invention relates to an application technology in the field of drug research, in particular to an anti-tumor cell relaxin alkaloid compound as well as preparation and application thereof. The alkaloid compounds are compounds 1-4 as shown in a formula I, the molecular formula of the compound 1 is C29H35NO4, and the structural formula of the compound 1 is 1 in the formula I; the molecular formula of the compound 2 is C29H35NO4, and the structural formula is 2 in the formula I; the molecular formula of the compound 3 is C29H35NO5, and the structural formula is 3 in the formula I; the molecular formula of the compound 4 is C29H39NO5, and the structural formula is 4 in the formula I. Compared with a traditional chemical synthesis route, the method adopts a microbial fermentation technology to realize preparation of the target compound, not only avoids complex organic synthesis steps and use of expensive and toxic reagents, but also has the characteristics of simple and convenient process flow, mild culture conditions, shorter production period, lower raw material cost and the like, is suitable for large-scale production, and has a wide application prospect. The invention provides an economic and sustainable preparation way for subsequent drug development, and shows a good application prospect in the field of antitumor drug research and development.

The present disclosure provides relaxin-2 fusion protein analogs with enhanced in vivo half-lives and methods for making same. Also disclosed herein are methods of treating relaxin-2-associated disorders or diseases using the relaxin-2 fusion protein analogs described herein.

The present disclosure relates to pharmaceutical formulations comprising heterodimeric relaxin fusion polypeptides, particularly heterodimeric relaxin 2 fusion polypeptides, and uses thereof. Thus, the present disclosure provides pharmaceutical formulations comprising relaxin fusion polypeptides and kits comprising the pharmaceutical formulations as well as uses thereof, including methods of treatment. The pharmaceutical formulations of the present disclosure are particularly useful in the treatment of cardiovascular diseases, such as in the treatment of heart failure.

The invention relates to the technical field of dog and cat breeding health detection, in particular to a pregnancy detection kit and method for rapidly and quantitatively detecting dog and cat relaxin, and a sample processing unit is used for completing collection and pretreatment of dog and cat samples; a sample detection area, a quality control area, a water absorption area and a sample adding area are sequentially arranged on the detection card body; a standard curve reference module is arranged in the quantitative reference unit, and the standard curve reference module is a chip or a paper reference card used for storing standard curve data; the signal processing and output unit comprises a signal reading module, a result storage module and a transmission module, and the result storage and transmission module is used for recording detection data; the environment control unit comprises a temperature control module, the specific reaction efficiency and the signal stability are ensured, and the technical problems that in an existing dog and cat pregnancy detection technology, detection is slow, quantification is difficult, samples are limited, the environment is sensitive, and data are difficult to manage are solved.

The present invention relates to heterodimeric relaxin fusion polypeptides, in particular to heterodimeric relaxin 2 fusion polypeptides and uses thereof. Accordingly, the present invention provides relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same as well as uses thereof including therapeutic methods. The polypeptides and compositions of the present invention are particularly useful for the treatment of cardiovascular diseases, for example for the treatment of heart failure.

Relaxin (RLN) analogs are disclosed including modifications that increase half-life when compared to native, human RLN, that maintain selectivity to the RXFP1 receptor and that provide in vitro and in vivo stability for improved druggability properties and less immunogenicity. Pharmaceutical compositions also are disclosed that include one or more of the RLN analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the RLN analogs also are disclosed, especially for treating cardiovascular, pulmonary and / or renal conditions, diseases or disorders.

The invention belongs to the technical field of tumor prevention and treatment, and particularly relates to a nano-drug capable of simultaneously inhibiting fibroblast activation and angiogenesis. The nano-drug for simultaneously inhibiting fibroblast activation and angiogenesis is a bionic nano-carrier SNPs (Single Nucleotide Polymorphism) loaded with modified relaxin analogue polypeptide B7-33. The bifunctional bionic nano-drug B7-33-SNPs adopted by the invention can be delivered to tumor tissues in a targeted manner, and meanwhile, the fibroblast activation-mediated extracellular matrix and angiogenesis are inhibited, and the fibroblast activation-mediated angiogenesis is also inhibited. The results can lay a good technical foundation for targeted prevention and treatment of bile duct cancer, and provide a new technical thought for prevention and treatment of other diseases.

The present disclosure provides relaxin-2 fusion protein analogs with enhanced in vivo half-lives and methods for making same. Also disclosed herein are methods of treating relaxin-2-associated disorders or diseases using the relaxin-2 fusion protein analogs described herein.

The present application relates to a kind of traditional Chinese medicine composition for treating ischemic heart failure and preparation method thereof, belong to the field of traditional Chinese medicine pharmacy, the traditional Chinese medicine composition includes: cassia 5-15 parts, white atractylodes 5-15 parts, poria 5-15 parts, dried ginger 6-12 parts, acanthopanax 5-15 parts, water red flower seed 10-30 parts, verbena 3-9 parts, dogwood 6-12 parts, fried licorice 3-9 parts.The composition can significantly reduce N-terminal B-type natriuretic peptide level, significantly improve model rat heart tissue pathological changes, regulate the heart function of model rat, improve the systolic function of heart, and can reduce the expression of rat interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha and other inflammatory factors, involve extracellular matrix receptor interaction, chemotactic factor signal pathway, relaxin signal pathway, cyclic adenosine monophosphate signal pathway, nuclear factor-kappa B signal pathway and multiple pathways, and is effective drug for treating ischemic heart failure.

Relaxin-2 fusion protein analogs with enhanced in vivo half-life and methods for making the same are described. Also described are methods of treating relaxin-2-associated disorders or diseases using the relaxin-2 fusion protein analogs.

Provided herein are small molecule modulators of RXFP1, and methods of making and use thereof. These compounds are pharmacological mimetics of relaxin H2 signaling and are capable of activating RXFP1. This activation triggers intracellular signaling pathways that mediate physiological functions in many tissues, including the reproductive, cardiovascular, renal, hepatic, and connective tissues. As such, these compounds are useful in the treatment of a variety of indications, including heart failure and other RXFP1 related diseases in patients in need thereof.